A global shortage of GLP-1 receptor agonists is prompting healthcare providers to implement strict triage guidelines. Rapidly expanding off-label usage for weight management has outpaced production capacity for active pharmaceutical ingredients.
Manufacturing Deficits
Complex sterile filling operations represent the primary bottleneck in the GLP-1 supply chain. Leading producers are investing heavily in new facility acquisitions, but operational ramp-ups will require up to 24 months.
Clinical Realignment
Endocrinologists are advising health systems to prioritize patients with severe type 2 diabetes and advanced cardiovascular risks. Meanwhile, compounding pharmacies face heightened regulatory scrutiny over generic alternative formulations.